Ronnel, also known as fenchlorphos, is an organophosphate insecticide that was widely used in the past to control pests such as flies, ticks, and mites. Its synthesis involves the reaction of phosphorus oxychloride with 2,4-dichlorophenol and then with 2,2-dichlorovinyl dimethyl phosphate. Ronnel acts by inhibiting acetylcholinesterase, an enzyme essential for nerve transmission. This inhibition can lead to a buildup of acetylcholine, resulting in a range of effects including muscle tremors, weakness, paralysis, and respiratory failure. While Ronnel was once used widely, its use has been restricted or banned in many countries due to its toxicity to mammals and the potential for environmental contamination. However, it remains in use in some areas for the control of certain pests, particularly in veterinary medicine. Despite its toxicity, Ronnel has been studied for its potential to inhibit cancer cell growth and for its potential to be used as a biocontrol agent. Research on Ronnel is ongoing to understand its environmental fate and to develop safer alternatives.'
ronnel: FENCHLORPHOS was heading 1972-95 (Prov 1972-73); RONNEL was see FENCHLORPHOS 1975-95; use FENCHLORPHOS (NM) to search FENCHLORPHOS 1972-95 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9298 |
| CHEMBL ID | 1871418 |
| CHEBI ID | 82125 |
| SCHEMBL ID | 19438 |
| MeSH ID | M0242772 |
| Synonym |
|---|
| phosphorothioic acid, o,o-dimethyl o-(2,4,5-trichlorophenyl) ester |
| o-(2,4,5-tricloro-fenil)-o,o-dimetil-monotiofosfato [italian] |
| ronnel [usan] |
| o,o-dimethyl-o-(2,4,5-trichlorphenyl)-thionophosphat [german] |
| phenol, 2,4,5-trichloro-, o-ester with o,o-dimethyl phosphorothioate |
| dermaphos |
| nsc 8926 |
| fenclofosum [inn-latin] |
| phenol, 2,4,5-trichloro-, o-ester with o,o-dimethylphosphorothioate |
| trichlormetaphos |
| dimethyl (2,4,5-trichlorophenyl) phosphorothionate |
| o-(2,4,5-trichloor-fenyl)-o,o-dimethyl-monothiofosfaat [dutch] |
| dermafosu [polish] |
| fenchlorphos [iso] |
| caswell no. 724 |
| fenchloorfos [dutch] |
| hsdb 667 |
| o-(2,4,5-trichlor-phenyl)-o,o-dimethyl-monothiophosphat [german] |
| o,o-dimethyl o-(2,4,5-trichlorophenyl)thiophosphate |
| einecs 206-082-6 |
| fenchlorfosu [polish] |
| thiophosphate de o,o-dimethyle et de o-(2,4,5-trichlorophenyle) [french] |
| smear |
| epa pesticide chemical code 058301 |
| brn 1885571 |
| ronnel [ansi] |
| dimethyl trichlorophenyl thiophosphate |
| ai3-23284 |
| o,o-dimethyl o-(2,4,5-trichlorophenyl) phosphorothioate |
| korlane |
| phenol,4,5-trichloro-, o-ester with o,o-dimethyl phosphorothioate |
| thiophosphate de o,4,5-trichlorophenyle) |
| dow et 14 |
| fenchloorfos |
| korlan |
| etrolene |
| nanchor |
| nanker |
| nsc-8926 |
| trichlorometafos |
| viozene |
| et 57 |
| nankor |
| o,4,5-trichlorophenyl) phosphorothioate |
| oms 123 |
| dimethyl (2,5-trichlorophenyl) phosphorothionate |
| rovan |
| et 14 |
| trolene |
| fenchlorophos |
| trolene 20l |
| phosphorothioic acid,o-dimethyl o(2,4,5-trichlorophenyl) ester |
| fenchlorphos |
| 299-84-3 |
| fenchlorfos |
| remelt |
| o-(2,5-trichloor-fenyl)-o,o-dimethyl-monothiofosfaat |
| dermafos |
| phosphorothioic acid,o-dimethyl o-(2,4,5-trichlorophenyl) ester |
| fenclofos |
| o-(2,5-trichlor-phenyl)-o,o-dimethyl-monothiophosphat |
| ectoral |
| o-(2,5-tricloro-fenil)-o,o-dimetil-monotiofosfato |
| troline |
| blitex |
| trolen |
| phenchlorfos |
| nsc8926 |
| gesektin k |
| wln: gr bg dg eops & o1 & o1 |
| ronnel |
| o,4,5-trichlorophenyl) thiophosphate |
| ent 23,284 |
| moorman's medicated rid-ezy |
| moor man's medicated rid-ezy |
| dow et 57 |
| fenclofos (inn) |
| ronnel (usan) |
| D05753 |
| ronnel, analytical standard |
| NCGC00163886-01 |
| HMS2093B20 |
| NCGC00163886-03 |
| NCGC00163886-02 |
| C18986 |
| dtxcid0014885 |
| dtxsid2034885 , |
| cas-299-84-3 |
| tox21_301334 |
| NCGC00255659-01 |
| tox21_113416 |
| tox21_113425 |
| ent-23284 |
| oms-123 |
| fenclorfos |
| fenclorvur |
| chebi:82125 , |
| CHEMBL1871418 |
| trichlorometaphos |
| fenchlorfosu |
| o-(2,4,5-tricloro-fenil)-o,o-dimetil-monotiofosfato |
| unii-89rag7sb3b |
| o-(2,4,5-trichlor-phenyl)-o,o-dimethyl-monothiophosphat |
| fenclofosum |
| fenclofos [inn] |
| thiophosphate de o,o-dimethyle et de o-(2,4,5-trichlorophenyle) |
| o,o-dimethyl-o-(2,4,5-trichlorphenyl)-thionophosphat |
| o-(2,4,5-trichloor-fenyl)-o,o-dimethyl-monothiofosfaat |
| dermafosu |
| 89rag7sb3b , |
| fenclos |
| AKOS015888330 |
| ronnel [mi] |
| ronnel [green book] |
| ronnel [hsdb] |
| o,o-dimethyl o-2,4,5-trichlorophenyl phosphorothioate |
| CCG-213503 |
| SCHEMBL19438 |
| NCGC00163886-05 |
| tox21_113416_1 |
| CS-4660 |
| dimethyl o-(2,4,5-trichlorophenyl) thiophosphate |
| o,o-dimethyl o-(2,4,5-trichlorophenyl) phosphorothionate |
| o,o-dimethyl o-(2,4,5-trichlorophenyl) thiophosphate |
| HY-B1093 |
| AB01563101_01 |
| fenchlorphos, pestanal(r), analytical standard |
| fenchlorphos 100 microg/ml in cyclohexane |
| fenchlorphos 10 microg/ml in cyclohexane |
| J-017721 |
| SBI-0206816.P001 |
| dimethoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-$l^{5-phosphane |
| phosphorothioic acid, o-(2,4,5-trichlorphenyl)-, o,o-dimethyl ester |
| DB11456 |
| Q1853255 |
| dimethoxy-sulfanylidene-(2,4,5-trichlorophenoxy)-lambda5-phosphane |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Guthion and coumaphos, although highly toxic by topical application, were both ineffective as contact insecticides when applied as solids in suspension." | ( The toxicity of some organophosphorus compounds to adult Anopheles stephensi. BARLOW, F; HADAWAY, AB, 1963) | 0.24 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fenthion and malathion were the most promising of the compounds, and wettable powder deposits at a dosage of 1 g/m(2) on plywood remained effective for five months." | ( The toxicity of some organophosphorus compounds to adult Anopheles stephensi. BARLOW, F; HADAWAY, AB, 1963) | 0.24 |
| Class | Description |
|---|---|
| organic thiophosphate | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 24.1826 | 0.0072 | 15.7588 | 89.3584 | AID1224835; AID624030 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 43.6486 | 0.0025 | 41.7960 | 15,848.9004 | AID1347398 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 42.9692 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
| AR protein | Homo sapiens (human) | Potency | 30.7121 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743036; AID743042 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 29.7746 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 0.4772 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 59.9914 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.4199 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.7669 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743078; AID743079 |
| G | Vesicular stomatitis virus | Potency | 6.9178 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 54.5514 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 0.0061 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 27.7643 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 23.7101 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 22.7421 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 21.7498 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID743202; AID743219 |
| Interferon beta | Homo sapiens (human) | Potency | 8.7231 | 0.0033 | 9.1582 | 39.8107 | AID1347407; AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 6.9178 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 6.9178 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 54.0951 | 0.0119 | 17.9420 | 71.5630 | AID651632 |
| Ataxin-2 | Homo sapiens (human) | Potency | 54.0951 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 6.9178 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 18 (64.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 6 (21.43) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 30 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||